SCHEMBL554569

SCHEMBL554569

Cc1nc2cc(C(=O)O)ccc2n1C

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.64
MEN1 O00255 1/20 0.63
KMT2A Q03164 1/20 0.63
HTT P42858 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.58
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
MAPT P10636 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
POLB P06746 1/20 0.57
NAMPT P43490 1/20 0.55
HCAR3 P49019 1/20 0.55
LMNA P02545 1/20 0.54
THRB P10828 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
HSP90AA1 P07900 1/20 0.52
HSP90AB1 P08238 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18247596 0.87 TDP1 (0.53) HSD17B10MEN1KMT2AHTTL3MBTL1
SCHEMBL6112696 0.87 RAB9A (0.72) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL3727866 0.85 KMT2A (0.67) HSD17B10MEN1KMT2ANPC1RAB9A
SCHEMBL25315207 0.84 HDAC1 (0.67) HSD17B10HTTMAPTNAMPTHCAR3
SCHEMBL1144927 0.83 HCAR3 (0.55) HSD17B10HTTL3MBTL1SMN1; SMN2HCAR3
SCHEMBL31489 0.83 RAB9A (0.72) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL29989068 0.83 RAB9A (0.72) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL6320502 0.83 HDAC6 (0.53) HSD17B10HTTL3MBTL1NPC1RAB9A
SCHEMBL13907804 0.83 TDP1 (0.57) HSD17B10MEN1KMT2AHTTL3MBTL1
SCHEMBL15000608 0.83 KMT2A (0.59) HSD17B10MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2978750-B1 \"SYNTHESIS OF DABIGATRAN\ USV PRIVATE LTD (IN) 2020-03-04 EP claimed
US-9688657-B2 Synthesis of dabigatran USV PRIVATE LIMITED (IN) 2017-06-27 US claimed
US-20160060248-A1 SYNTHESIS OF DABIGATRAN USV PRIVATE LIMITED (IN) 2016-03-03 US claimed
EP-2978750-A2 \"SYNTHESIS OF DABIGATRAN\ USV Limited (IN) 2016-02-03 EP claimed
WO-2014167577-A2 \"SYNTHESIS OF DABIGATRAN\ USV LIMITED (IN) 2014-10-16 WO claimed
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2010-09-30 US claimed
US-12378463-B2 Water-based resin with elasticity for applications in cementing and subterranean structures SAUDI ARABIAN OIL COMPANY (SA) 2025-08-05 US disclosed
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 CN disclosed
US-20240093081-A1 WATER-BASED RESIN WITH ELASTICITY FOR APPLICATIONS IN CEMENTING AND SUBTERRANEAN STRUCTURES SAUDI ARABIAN OIL COMPANY (SA) 2024-03-21 US disclosed
US-11795367-B2 Water-based resin with elasticity for applications in cementing and subterranean structures SAUDI ARABIAN OIL COMPANY (SA) 2023-10-24 US disclosed
US-11708522-B1 Water-based hydrogel polymer composition and methods of treating subterranean formations or cement constructions comprising contaminants SAUDI ARABIAN OIL COMPANY (SA) 2023-07-25 US disclosed
US-20220017811-A1 WATER-BASED RESIN WITH ELASTICITY FOR APPLICATIONS IN CEMENTING AND SUBTERRANEAN STRUCTURES SAUDI ARABIAN OIL COMPANY (SA) 2022-01-20 US disclosed
WO-2022015932-A1 WATER-BASED RESIN WITH ELASTICITY FOR APPLICATIONS IN CEMENTING AND SUBTERRANEAN STRUCTURES SAUDI ARABIAN OIL COMPANY (SA) 2022-01-20 WO disclosed
WO-2004067529-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS ELI LILLY AND COMPANY (US) 2004-08-12 WO disclosed
EP-0351856-B1 Thiazolo[5,4-b]azepine compounds TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1999-09-15 EP disclosed
US-5300639-A 2-oxo-3-carbonylamino-substituted azepine intermediates; lipoperoxide formation inhibitors TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-04-05 US disclosed
US-5118806-A Enzyme inhibitor for lipoxygenase; useful for treating cancer, hepatic diseases, inflammation, cerebrovascular diseases TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-06-02 US disclosed
US-5108485-A Controlling monocotyledonous and dicotyledonous plants AMERICAN CYANAMID COMPANY (US) 1992-04-28 US disclosed
US-4956360-A LIPOPEROXIDE INHIBITORS, ENZYME INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1990-09-11 US disclosed
EP-0351856-A2 Thiazolo[5,4-b]azepine compounds Takeda Chemical Industries, Ltd. (JP) 1990-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060248-A1 SYNTHESIS OF DABIGATRAN ESD, F2, PROC HSD17B10 2678/4885MEN1 3712/4885KMT2A 1977/4885
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE FSHR, GNRHR, SHBG HSD17B10 3064/4885MEN1 150/4885KMT2A 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.